SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a central topic of discussion, driven by its presentation at the J.P. Morgan Healthcare Conference, alongside recent announcements including the appointment of a Chief Commercial Officer and completion of enrollment for its VK2735 maintenance dosing study. The community is sharply divided: bulls emphasize the drug's "best-in-class" potential, robust clinical data, and strategic leadership moves positioning the company for significant partnerships in the rapidly expanding GLP-1 obesity market. Conversely, skeptics point to persistent stock underperformance, past insider selling, and the formidable competition, questioning the company's ability to capitalize on its assets and anticipating a "sell the news" reaction from the conference.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as market participants navigate concerns over renewed tariff threats and a deepening debate around Federal Reserve independence. Despite these geopolitical and monetary policy uncertainties, the community notes a remarkably resilient market where dips are consistently bought, fueling discussions about a potential AI-driven 'zombie grind higher' and its long-term sustainability.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is a focal point of market discussion following its new "Meta Compute" initiative and recent nuclear energy partnerships aimed at powering its extensive AI infrastructure buildout. While these ambitious investments underline a long-term strategic shift towards AI, community sentiment is divided, with many debating the immediate impact on the stock amid reports of job cuts in the Reality Labs division. Investors are closely scrutinizing whether this significant capital allocation will translate into tangible returns and address the company's recent price stagnation compared to other tech giants.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is generating significant excitement following a new pre-production order from a major U.S. defense contractor for AI-powered vision systems, coupled with a strategic asset sale to sharpen its core focus. The community is actively anticipating a much larger military contract and is bullish on OSS's undervalued position within the rapidly growing Edge AI and defense sectors, noting its notably low share float as a factor for potential rapid movement.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing strong upward momentum, driven by growing optimism for its Artificial Intelligence and Cloud divisions. The community is buzzing about this breakout, fueled by reports of resumed high-performance AI chip shipments to China and a broader positive sentiment shift toward the Chinese tech sector. Many anticipate a significant re-rating as investors eye reallocation into these names.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively discussed as the market evaluates new 25% tariffs imposed on countries trading with Iran, fueling community debate on potential trade war implications, particularly with China. This geopolitical development unfolds as investors anticipate the upcoming CPI report, amid widespread discussion about market resilience despite ongoing concerns surrounding political influence on economic data and the Federal Reserve.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending due to the FDA's decision to waive the Advisory Committee meeting for its FILSPARI supplemental New Drug Application in Focal Segmental Glomerulosclerosis (FSGS). The community interprets this as a significant de-risking signal, fostering optimism for a potential approval given the high unmet need for FSGS treatments. With FILSPARI already approved for IgA nephropathy, the focus is on this crucial label expansion and its implications for the company's market position.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is a focal point of discussion following a substantial stock price correction, as investors weigh a CFO transition and positive preliminary Q4 user growth against broader concerns. The community is sharply divided, with bulls highlighting the company's strong user engagement, expanding product offerings, and perceived undervaluation, especially after a recent analyst upgrade. Conversely, bears express skepticism over Duolingo's long-term viability in the face of rapidly advancing AI technologies and question management's focus on user growth over immediate profitability.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is seeing a surge in discussion following reports confirming its multi-year partnership with Google, integrating Gemini AI into Siri and upcoming Apple Intelligence features. This news is largely being met with optimism, addressing investor concerns about Apple's AI strategy by clarifying its roadmap without extensive capital expenditure. The community is actively debating whether this strategic collaboration will propel the stock to new highs, especially with upcoming earnings on the horizon.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is a major topic of conversation amid renewed speculation about Roaring Kitty's potential re-emergence and discussion of CEO Ryan Cohen's performance-based compensation plan targeting a substantial market cap increase. The community is sharply divided, with bulls anticipating a significant move or short squeeze while bears point to fading momentum and continued low trading volume. This ongoing debate highlights deep-seated convictions and concerns about market dynamics surrounding the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.”</li><li>Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment.</li><li>Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025.</li></ul> Shares of Sarepta Therapeutics Inc. (SRPT) sank 12% on Monday after the company said that it expects full year 2025 net product revenue of $1.86 billion, marking only slight growth from the $1.79 billion reported for full year 2024.Net product revenue refers to the company’s revenue from its products and does not include collaboration, contract manufacturing or royalty revenue.Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025, according to data from Fiscal AI.<h2 class="st-heading-2">Results Breakdown</h2>Sarepta <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-reports-preliminary-fourth-quarter-and-full-year-2025">now sees</a> revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million, including fourth quarter revenue of $110.4 million. The company said that the therapy’s revenue in the three months through the end of December was impacted by the year-end flu season and the need to reschedule six patient infusions into 2026.Revenue from the company’s other therapies for the full year is now expected at $965.6 million.Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” “We have important initiatives in 2026 to continue the success of our approved therapies, particularly ELEVIDYS. We previously set a yearly sales floor for ELEVIDYS of $500.0 million. We reconfirm that floor and our intentions to exceed it,” Ingram said on Monday.The company further added that it had $953.8 million in preliminary cash, cash equivalents, restricted cash and investments as of 2025-end. The company will announce its full financial results in late February.<h2 class="st-heading-2">Elevidys Safety Concerns And Other Setbacks</h2>The preliminary numbers come in light of a challenging year for the company. Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure. DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration.While Sarepta resumed shipments to DMD patients who can walk after a temporary pause, it is now developing a risk-mitigation approach for patients who cannot walk to resume shipments in the particular patient segment.In November, the company also announced that its two approved therapies Amondys 45 and Vyondys 53 in DMD failed in a key confirmatory trial aimed at a traditional full approval for the two. The company, however, continues to eye traditional approval based on the positive risk-benefits of the therapies and real-world evidence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from 'high’ to 'extremely high' levels.A Stocktwits user dismissed the sell-off and opined that the “Elevidys story isn’t broken.” They also noted that the company has enough cash to cover liabilities.<stembedurl>https://www.stocktwits.com/Initiator1/message/641562456</stembedurl>Another dismissed the selloff as a "minor setback."<stembedurl>https://www.stocktwits.com/ZzyzxResearch/message/641561010</stembedurl><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 82% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-lvlu-stock-surge-today/cmUaI8XR4Eo">Why Did LVLU Stock More Than Double Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns

Sarepta now sees revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million.

Equity

Sarepta now sees revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million.


Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been assigned an average rating of "Hold" from the thirty brokerages that are currently covering the stock, Marketbeat...

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntingtons Disease

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101...

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare...

Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4,033.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation...

Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

Voya Investment Management LLC trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.5% during the third quarter, according to its most recent 13F filing with the SEC. The...

Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT

Assenagon Asset Management S.A. reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 96.6% in the third quarter, according to the company in its most recent...

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5% - Here's What Happened

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 3.5% - Time to Buy...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SRPT News

SRPTSarepta Therapeutics Inc